DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine

Information source: California Medical Clinic for Headache
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acute Migraine; Migraine Headache; Headache Disorders

Intervention: Zolmitriptan 5 mg Nasal Spray (Drug); Eletriptan 40 mg tablet (Drug)

Phase: N/A

Status: Completed

Sponsored by: California Medical Clinic for Headache

Official(s) and/or principal investigator(s):
David B Kudrow, MD, Principal Investigator, Affiliation: California Medical Clinic for Headache

Summary

The purpose of this study is to Compare the efficacy of zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet in the acute treatment of migraine. To develop and evaluate a set of importance weights for a predefined set of treatment attributes for migraine suffers using zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet. To contrast the efficacy of zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet at early time points. To analyze the patterns of self-reported tolerability of migraine sufferers using zolmitriptan 5 mg nasal spray vs. eletriptan 40 mg tablet.

Clinical Details

Official title: Zolmitriptan Nasal Spray VS Eletriptan in the Acute Treatment of Migraine

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Reduction of migraine headache pain from mild, moderate or severe to pain free.

Secondary outcome: Reduction of migraine headache pain from mild, moderate or severe to pain free.

Detailed description: An open-label, randomized, cross-over study comparing the efficacy of zolmitriptan 5 mg nasal spray with eletriptan 40 mg tablet at early time points. Satisfaction endpoints include global assessment of preference, overall satisfaction and effectiveness as well as tolerability of both medications.

Eligibility

Minimum age: 15 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 15 to 70 years old

- Migraine attacks according to the criteria proposed by the IHS

- 3-12 Migraine attacks per month

- adequate contraception

- Willing and able to give written informed consent

- Willing and able to complete the entire course of the study & comply with

instructions

- Stable dose of preventive medication for at least 4 weeks

Exclusion Criteria:

- Disorders listen in groups 5-11 of the IHS Classification

- Subject is pregnant or lactating.

- Significant medical or psychiatric disease

- Subject has a history of symptoms suggestive of ischemic heart disease (angina,

myocardial infarction, documented silent ischemia) or other vascular disease, including Prinzmetal angina, claudication, Wolff-Parkinson-White syndrome, or other cardiac accessory conduction pathway arrhythmia

- Subject has uncontrolled hypertension.

- Subject has history of basilar, ophthalmoplegic, or hemiplegic migraine or serious

neurologic condition associated with headache

- Subject has used monoamine oxidase A inhibitors (MAOI-As) within 2 weeks of

randomization

- Subject has had serious adverse event while using another 5-HT agonist, or previous

serious adverse event while using zolmitriptan or hypersensitivity to zolmitriptan or eletriptan

- Using CYP3A4 inhibitors listed by the FDA as contraindicated with eletriptan

- Moderate/severe hepatic/renal impairment

- Subject currently using cimetidine

- Concomitant medication treatment with a triptan, ergotamine or methysergide.

Locations and Contacts

California Medical Clinic for Headache, Santa Monica, California 90404, United States
Additional Information

Starting date: April 2008
Last updated: January 13, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017